Zylox-Tonbridge Medical Technology Co., Ltd, a pioneer in neurovascular and peripheral vascular interventional technologies, recently held its Investor Open Day at the Zhuhai Innovation Center, hosting close to 150 institutional investors and sell-side analysts.
The event outlined the Company’s vision for establishing a globally competitive vascular intervention ecosystem, built on robust research and development, scalable manufacturing capabilities, and a growing international commercial presence. Through executive briefings, live product showcases, and guided facility tours, attendees gained in-depth insight into how Zylox-Tonbridge integrates innovation, operational excellence, and worldwide market execution to drive long-term value creation.
A Distinctive Innovation Platform Driving Precision Endovascular Treatment
Zylox-Tonbridge presented a comprehensive lineup of approved products alongside advanced pipeline candidates, demonstrating the expanding strength and technical sophistication of its endovascular solutions across neurovascular and peripheral vascular applications.
Highlighted products included:
ZYLOX Mammoth Large-Bore Thrombectomy Catheter — the only 12F–18F peripheral thrombectomy catheter available in China, featuring a proprietary flared-tip design that enhances clot extraction efficiency in deep vein thrombosis (DVT) procedures. Feilong Embolization Assist Stent — China’s first device in its segment to incorporate DFT (Drawn Filled Tubing) braided technology, delivering full-length radiopacity to improve procedural accuracy and physician confidence. The event outlined the Company’s vision for establishing a globally competitive vascular intervention ecosystem, built on robust research and development, scalable manufacturing capabilities, and a growing international commercial presence. Through executive briefings, live product showcases, and guided facility tours, attendees gained in-depth insight into how Zylox-Tonbridge integrates innovation, operational excellence, and worldwide market execution to drive long-term value creation.
A Distinctive Innovation Platform Driving Precision Endovascular Treatment
Zylox-Tonbridge presented a comprehensive lineup of approved products alongside advanced pipeline candidates, demonstrating the expanding strength and technical sophistication of its endovascular solutions across neurovascular and peripheral vascular applications.
Highlighted products included:
The Company also emphasized its image-guided endovascular therapy platform, anchored by its intravascular optical coherence tomography (OCT) system and the ZYLOX Pantheris atherectomy catheter. As the only commercially available solution worldwide offering real-time, visualization-guided plaque excision in peripheral arteries, this platform marks a major step forward in precision-driven endovascular intervention—an increasingly important benchmark in global clinical practice.
Innovation and Global Expansion Powering Long-Term Growth
In discussions with investors, Zylox-Tonbridge’s leadership detailed its growth strategy, which integrates continuous product innovation, industrialized manufacturing scale, and international commercial expansion.
Dr. Jonathon Zhong Zhao, Chairman and Chief Executive Officer, stated, “Our goal is to position Zylox-Tonbridge as a globally competitive vascular intervention leader by pairing clinically impactful innovation with scalable manufacturing and a fast-growing global commercial network. This integrated approach enables us to convert R&D strength into sustainable, long-term growth worldwide.”
By 2025, Zylox-Tonbridge products had been used in more than one million procedures, reflecting strong adoption and trust among clinicians.
The Company’s global footprint continues to broaden. As of the end of 2025, Zylox-Tonbridge had achieved commercial presence in 83 countries and regions and established partnerships with over 80 distributors and commercial collaborators globally. Looking ahead, the Company plans to further reinforce its global operating infrastructure—including regulatory capabilities, manufacturing systems, quality management, and market execution—to support continued organic growth and targeted expansion across key international medtech markets.
Innovation and Global Expansion Powering Long-Term Growth
In discussions with investors, Zylox-Tonbridge’s leadership detailed its growth strategy, which integrates continuous product innovation, industrialized manufacturing scale, and international commercial expansion.
Dr. Jonathon Zhong Zhao, Chairman and Chief Executive Officer, stated, “Our goal is to position Zylox-Tonbridge as a globally competitive vascular intervention leader by pairing clinically impactful innovation with scalable manufacturing and a fast-growing global commercial network. This integrated approach enables us to convert R&D strength into sustainable, long-term growth worldwide.”
By 2025, Zylox-Tonbridge products had been used in more than one million procedures, reflecting strong adoption and trust among clinicians.
The Company’s global footprint continues to broaden. As of the end of 2025, Zylox-Tonbridge had achieved commercial presence in 83 countries and regions and established partnerships with over 80 distributors and commercial collaborators globally. Looking ahead, the Company plans to further reinforce its global operating infrastructure—including regulatory capabilities, manufacturing systems, quality management, and market execution—to support continued organic growth and targeted expansion across key international medtech markets.